Lipoprotein-Associated Phospholipase A2: A Risk Marker or a Risk Factor?

Amir Lerman, Joseph P. McConnell

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Multiple cardiovascular biomarkers are associated with increased cardiovascular disease (CVD) risk. Lipoprotein-associated phospholipase A2 (Lp-PLA2) appears to be relatively unique in its high specificity for and the causal pathway of plaque inflammation. In both primary and secondary prevention study populations, Lp-PLA2 was consistently associated with higher cardiovascular risk, and the risk estimate appears to be relatively unaffected by adjustment for conventional CVD risk factors. Risk ratios were similar, whether the mass concentration or activity of the enzyme was measured. The purpose of this article is to review the evidence for the clinical utility of Lp-PLA2, both as a risk marker and as a risk factor involved in the causal pathway of plaque inflammation and the formation of rupture-prone plaque.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume101
Issue number12 SUPPL.
DOIs
StatePublished - Jun 16 2008

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Cardiovascular Diseases
Inflammation
Primary Prevention
Secondary Prevention
Rupture
Biomarkers
Odds Ratio
Enzymes
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lipoprotein-Associated Phospholipase A2 : A Risk Marker or a Risk Factor? / Lerman, Amir; McConnell, Joseph P.

In: American Journal of Cardiology, Vol. 101, No. 12 SUPPL., 16.06.2008.

Research output: Contribution to journalArticle

@article{77fe4025eac94de79f59d4eba27c09de,
title = "Lipoprotein-Associated Phospholipase A2: A Risk Marker or a Risk Factor?",
abstract = "Multiple cardiovascular biomarkers are associated with increased cardiovascular disease (CVD) risk. Lipoprotein-associated phospholipase A2 (Lp-PLA2) appears to be relatively unique in its high specificity for and the causal pathway of plaque inflammation. In both primary and secondary prevention study populations, Lp-PLA2 was consistently associated with higher cardiovascular risk, and the risk estimate appears to be relatively unaffected by adjustment for conventional CVD risk factors. Risk ratios were similar, whether the mass concentration or activity of the enzyme was measured. The purpose of this article is to review the evidence for the clinical utility of Lp-PLA2, both as a risk marker and as a risk factor involved in the causal pathway of plaque inflammation and the formation of rupture-prone plaque.",
author = "Amir Lerman and McConnell, {Joseph P.}",
year = "2008",
month = "6",
day = "16",
doi = "10.1016/j.amjcard.2008.04.014",
language = "English (US)",
volume = "101",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Lipoprotein-Associated Phospholipase A2

T2 - A Risk Marker or a Risk Factor?

AU - Lerman, Amir

AU - McConnell, Joseph P.

PY - 2008/6/16

Y1 - 2008/6/16

N2 - Multiple cardiovascular biomarkers are associated with increased cardiovascular disease (CVD) risk. Lipoprotein-associated phospholipase A2 (Lp-PLA2) appears to be relatively unique in its high specificity for and the causal pathway of plaque inflammation. In both primary and secondary prevention study populations, Lp-PLA2 was consistently associated with higher cardiovascular risk, and the risk estimate appears to be relatively unaffected by adjustment for conventional CVD risk factors. Risk ratios were similar, whether the mass concentration or activity of the enzyme was measured. The purpose of this article is to review the evidence for the clinical utility of Lp-PLA2, both as a risk marker and as a risk factor involved in the causal pathway of plaque inflammation and the formation of rupture-prone plaque.

AB - Multiple cardiovascular biomarkers are associated with increased cardiovascular disease (CVD) risk. Lipoprotein-associated phospholipase A2 (Lp-PLA2) appears to be relatively unique in its high specificity for and the causal pathway of plaque inflammation. In both primary and secondary prevention study populations, Lp-PLA2 was consistently associated with higher cardiovascular risk, and the risk estimate appears to be relatively unaffected by adjustment for conventional CVD risk factors. Risk ratios were similar, whether the mass concentration or activity of the enzyme was measured. The purpose of this article is to review the evidence for the clinical utility of Lp-PLA2, both as a risk marker and as a risk factor involved in the causal pathway of plaque inflammation and the formation of rupture-prone plaque.

UR - http://www.scopus.com/inward/record.url?scp=51749083479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51749083479&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2008.04.014

DO - 10.1016/j.amjcard.2008.04.014

M3 - Article

C2 - 18549867

AN - SCOPUS:51749083479

VL - 101

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12 SUPPL.

ER -